Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768024 | 0.77 | NOTUM (0.36) | CDK2MAOAMAOBLOXPARP1 | |
| SCHEMBL1405509 | 0.77 | NOTUM (0.36) | CDK2MAOAMAOBLOXPARP1 | |
| SCHEMBL26431777 | 0.72 | ALDH1A1 (0.34) | CDK2PARP1PARP10NOTUM | |
| SCHEMBL1405476 | 0.72 | NOTUM (0.50) | CDK2PARP1PARP10NOTUM | |
| SCHEMBL23384792 | 0.72 | UHRF1 (0.34) | CDK2PARP1PARP10NOTUM | |
| SCHEMBL24713940 | 0.72 | NOTUM (0.33) | CDK2PARP1PARP10NOTUM | |
| SCHEMBL29285141 | 0.71 | ERN1 (0.39) | ERN1PARP1PARP10 | |
| SCHEMBL29627844 | 0.70 | NOTUM (0.40) | ERN1PARP1PARP10NOTUM | |
| SCHEMBL5335092 | 0.70 | NOTUM (0.40) | ERN1PARP1PARP10NOTUM | |
| SCHEMBL31161543 | 0.69 | PARP10 (0.32) | CDK2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | ERN1 805/4885CDK2 392/4885MAOA 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.